il3-zetakine coupled to a cd33 costimulatory receptor as a dual-targeting car approach in aml
Published 1 year ago • 43 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:43
cd33-tim3 dual car t-cells enhance specificity of aml treatment
-
1:42
harnessing t-cells in acute leukemia and an anti-cd33/cd3 bite antibody
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
7:11
first-in-human cll1-cd33 compound car t-cells for aml
-
3:17
ziftomenib: mechanism of action and promising results in patients with kmt2ar or npm1m aml
-
10:20
eha22: time-limited venetoclax-obinutuzumab /- ibrutinib is superior to chemoimmunotherapy in ...
-
1:43
gilteritinib monotherapy vs combination therapy in r/r flt3-mutated aml
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:42:05
3rd year anniversary accounting pifolz
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
16:53
[quality] q3e
-
2:44
the tk008 phase iii trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
-
0:17
video 3 cianchi g et al, echo-guided insertion of a dual-lumen cannula vv ecmo
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
2:42
triplet combination of azacitidine, venetoclax & gilteritinib for patients with flt3-mutated aml
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
6:03
chi3l1 and antitumor responses
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
1:40
pivekimab sunirine in combination with venetoclax and azacitidine for cd123-positive aml
-
1:49
bringing precision medicine and mrd into clinical strategies